Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription Articles published in Leuk Res Retrieve available abstracts of 195 articles: HTML format

Single Articles

June 2026
1. HALDER R, Singh R, Rainchwar S, Bhatnagar S, et al
   Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study.
   Leuk Res. 2026;165:108218.
   PubMed     Abstract available
   
   
   May 2026
2. CHOWDHURY S, Mandal C, Sarkar S, Bag AK, et al
   Retraction notice to "Mobilization of lymphoblasts from bone marrow to peripheral blood in childhood acute lymphoblastic leukaemia: Role of 9-O-acetylated sialoglycoproteins" [Leukemia Res. 36(2) (2012) 146-155].
   Leuk Res. 2026 May 29:108240. doi: 10.1016/j.leukres.2026.108240.
   PubMed    
   
   
   
3. FAVRIN G, Cappello E, Rattotti S, Picone C, et al
   Regression of T-LGL leukemia in a patient treated with sildenafil for pulmonary hypertension.
   Leuk Res. 2026;167:108257.
   PubMed    
   
   
   
4. GIORDANO U, Mordak-Domagala M, Piekarska A, Sadowska-Klasa A, et al
   Long-term outcomes of allogeneic hematopoietic stem cell transplantation in adult philadelphia chromosome-positive all treated with tyrosine kinase inhibitors in the pre-blinatumumab era. A retrospective analysis on behalf of the polish adult leukemia
   Leuk Res. 2026;167:108242.
   PubMed    
   
   
   
5. DONG D, Chen H, Li H, Luo D, et al
   Prognostic significance of PCR-based measurable residual disease post-induction and during consolidation in pediatric KMT2A-rearranged acute myeloid leukemia.
   Leuk Res. 2026;167:108256.
   PubMed     Abstract available
   
   
   
6. KIR S, Abdullayeva N, Yilmazer A, Saydam G, et al
   Clinical use and adverse effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: The role of comorbidities.
   Leuk Res. 2026 May 19:108251. doi: 10.1016/j.leukres.2026.108251.
   PubMed     Abstract available
   
   
   
7. WOUDBERG R, Meiring SM, Sinanovic E
   Economic burden of leukemia diagnosis and treatment in South Africa: A retrospective cost of illness analysis.
   Leuk Res. 2026;166:108252.
   PubMed     Abstract available
   
   
   
8. ZHANG X, Bustamante J, Stefani H, Lee H, et al
   Development and temporal validation of an interpretable point score for in-hospital mortality in CLL/SLL using the U.S. National Inpatient Sample, 2016-2022.
   Leuk Res. 2026;164:108199.
   PubMed     Abstract available
   
   
   April 2026
9. OZMEN D, Kurekci DD, Ozkocaman V, Altindag Avci B, et al
   Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review.
   Leuk Res. 2026;166:108239.
   PubMed     Abstract available
   
   
   
10. SLATER VE, McDowell BD, Chrischilles EA
    Assessing the value of measuring frailty in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Res. 2026;166:108238.
    PubMed     Abstract available
    
    
    
11. KIR S, Abdullayeva N, Yilmazer A, Saydam G, et al
    Clinical use and adverse effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: The role of comorbidities.
    Leuk Res. 2026;166:108235.
    PubMed     Abstract available
    
    
    
12. YUAN F, Zhao X, Lin X, Wang J, et al
    Risk factors and fluid management in tumor lysis syndrome of acute myeloid leukemia: A retrospective study.
    Leuk Res. 2026;166:108232.
    PubMed     Abstract available
    
    
    
13. MUKAE J, Sadato D, Toya T, Hirama C, et al
    Chronic neutrophilic leukemia with transformation to B-lymphoblastic leukemia.
    Leuk Res. 2026;166:108229.
    PubMed    
    
    
    
14. HOU R, An L, Guan H, Lei X, et al
    Systemic evaluation for extramedullary disease and treatment outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Leuk Res. 2026;165:108231.
    PubMed     Abstract available
    
    
    
15. SALTER B, Ge S, Berg T, Garcia-Horton A, et al
    Efficacy of hypomethylating agents in combination with venetoclax in relapsed/refractory acute myeloid leukemia: A systematic review and meta-analysis.
    Leuk Res. 2026;165:108227.
    PubMed     Abstract available
    
    
    
16. SCHUTTE D, Call EM, Furstenau M, Beckmann L, et al
    Retrospective, single-center analysis of second allogeneic stem cell transplantation versus non-transplant regimens for acute myeloid leukemia patients with relapse after first transplantation.
    Leuk Res. 2026;165:108228.
    PubMed     Abstract available
    
    
    
17. YAMAMOTO J, Yamamoto H, Watanabe O, Kuno M, et al
    Outcomes and prognostic factors of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and central nervous system involvement.
    Leuk Res. 2026;165:108226.
    PubMed     Abstract available
    
    
    
18. WANG N, Feng Z, Zheng H, Chen X, et al
    Diagnostic updates and research advances in AML-MR: Integrating molecular genetics and immune mechanisms.
    Leuk Res. 2026;163:108200.
    PubMed     Abstract available
    
    
    March 2026
19. ARAI Y, Katagiri S, Chi S, Yoshimoto G, et al
    Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling study.
    Leuk Res. 2026;164:108207.
    PubMed     Abstract available
    
    
    
20. CARRAWAY HE, DeAngelo DJ, Wang ES, Komrokji RS, et al
    Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025.
    Leuk Res. 2026;164:108203.
    PubMed     Abstract available
    
    
    
21. BRANDWEIN J, Szkotak A, Page D, Wang P, et al
    Impact of measurable residual disease on outcomes using a modified DFCI protocol for adults with BCR-ABL negative acute lymphoblastic leukemia.
    Leuk Res. 2026;164:108206.
    PubMed     Abstract available
    
    
    
22. AMBINDER A, Levis M, Wang X, Pratz K, et al
    A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy.
    Leuk Res. 2026;164:108204.
    PubMed     Abstract available
    
    
    
23. GOTO A, Iyama S, Yoshida M, Tatekoshi A, et al
    Emergence and continuous clonal evolution of a JAK2 exon 12-mutated myeloid clone after treatment for de novo acute myeloid leukemia.
    Leuk Res. 2026;163:108202.
    PubMed    
    
    
    
24. LU W, He Z, Huang X
    Integrative transcriptomic and machine learning analysis identifies core immune genes and pathways driving graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2026;163:108201.
    PubMed     Abstract available
    
    
    
25. VIEIRA MS, Marcondes NA, Rotta LN
    The emerging role of plasmacytoid dendritic cell proliferation in acute myeloid leukemia.
    Leuk Res. 2026;164:108198.
    PubMed     Abstract available
    
    
    
26. TSERTSVADZE T, Edwards K, John-Olabode S, Datikashvili-David I, et al
    Expression and signaling patterns of CD180/MD-1 and CD150 in Chronic Lymphocytic Leukaemia (CLL) cells.
    Leuk Res. 2026;162:108169.
    PubMed     Abstract available
    
    
    February 2026
27. WANG M, Li J
    Measurable residual disease detection in acute leukemia: Technological advances and clinical translation.
    Leuk Res. 2026;163:108197.
    PubMed     Abstract available
    
    
    
28. CHANG G, Gao H, Wei Y, Fu Q, et al
    Venetoclax and azacitidine versus CAG for unfit patients with newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Leuk Res. 2026;163:108187.
    PubMed     Abstract available
    
    
    
29. WANG WJ, Wang SA, Al-Atrash G, Fang H, et al
    T-cell mixed chimerism after allogeneic hematopoietic stem cell transplantation does not correlate with relapse in patients with acute myeloid leukemia.
    Leuk Res. 2026;162:108185.
    PubMed    
    
    
    
30. HOU HA, Getta B, Ahn JS, Elsouda D, et al
    Outcomes of patients with R/R FLT3(mut+) AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation.
    Leuk Res. 2026;162:108186.
    PubMed     Abstract available
    
    
    
31. MIYASHITA A, Basendwah AM, Fero H, Alabbas F, et al
    CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis.
    Leuk Res. 2026;162:108179.
    PubMed     Abstract available
    
    
    
32. BILANISHVILI A, Tsertsvadze T, Edwards K, John-Olabode S, et al
    The effect of IL-4 on CD180 expression and signalling in Chronic lymphocytic leukaemia (CLL).
    Leuk Res. 2026;161:108166.
    PubMed     Abstract available
    
    
    January 2026
33. KHAN A, Gajendra S, Singh VK, Thakral D, et al
    Single cell transcriptomics derived combinatorial markers distinguished leukemic stem cells from hematopoietic stem cells in acute myeloid leukemia.
    Leuk Res. 2026;161:108170.
    PubMed     Abstract available
    
    
    
34. HU X, Zhu H, Li C
    Discovery of METTL3 inhibitor C191-0266 as a leukemia therapeutic through targeted modulation of protective autophagy.
    Leuk Res. 2026;165:108167.
    PubMed     Abstract available
    
    
    
35. SAMMUT R, Benichou A, Wang C, Loschi M, et al
    Impact of autoimmune diseases or inflammatory manifestations on response and outcome in high-risk myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Res. 2026;161:108168.
    PubMed    
    
    
    
36. STERN MA, Klekovkina E, Nanos SM, Fuller-Thomson E, et al
    Juggling two worlds: Exploring the experiences of caregivers of patients with acute leukemia.
    Leuk Res. 2026 Jan 8:108154. doi: 10.1016/j.leukres.2025.108154.
    PubMed     Abstract available
    
    
    
37. ALHURAIJI A, Alhejazi A, Bagal B, Lin CY, et al
    Clinical characteristics, treatment pathway and resource utilisation for patients with chronic lymphocytic leukaemia: A multicentre retrospective study.
    Leuk Res. 2026;160:108152.
    PubMed     Abstract available
    
    
    
38. TSUKAHARA F, Kaji K, Maru Y
    Identification and characterization of peptidyl-prolyl isomerase Pin1 as a new regulatory component of BCR::ABL1 degradation.
    Leuk Res. 2026;160:108146.
    PubMed     Abstract available
    
    
    December 2025
39. STANGANELLI C, Cabrera J, Bender A, Agriello E, et al
    Double IGHV rearrangements in a Latin American cohort of chronic lymphocytic leukemia patients.
    Leuk Res. 2025;160:108151.
    PubMed    
    
    
    
40. COUCELO M, Sargas C, Ayala R, Larrayoz MJ, et al
    Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories.
    Leuk Res. 2025;160:108149.
    PubMed     Abstract available
    
    
    
41. OU J, Li J, Liu Q, Zhou H, et al
    Frequency and prognostic significance of RAS pathway alterations in adult acute lymphoblastic leukemia.
    Leuk Res. 2025;160:108155.
    PubMed     Abstract available
    
    
    
42. LOK V, Moffitt K, Sastow D, Medawar G, et al
    Clinical utility of interim bone marrow biopsies in FLT3 mutant acute myeloid leukemia.
    Leuk Res. 2025;161:108147.
    PubMed    
    
    
    
43. RONNACKER J, Urbahn MA, Reicherts C, Kolloch L, et al
    Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.
    Leuk Res. 2025;160:108153.
    PubMed     Abstract available
    
    
    
44. ZOU M, Wan B, Hu J
    Efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy or CAR-T cells for relapsed/refractory acute lymphoblastic leukemia: A multicenter phase ii trial.
    Leuk Res. 2025;160:108148.
    PubMed     Abstract available
    
    
    November 2025
45. HUNTER CJ, Chou A, Roeder H, Eighmy W, et al
    Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia.
    Leuk Res. 2025;160:108144.
    PubMed     Abstract available
    
    
    
46. JAIN P, Qazi I, Thompson J, Ganatra N, et al
    Neutropenic enterocolitis in acute myeloid leukemia: A nationwide inpatient cross-sectional study.
    Leuk Res. 2025;160:108142.
    PubMed     Abstract available
    
    
    
47. TIAN S, Wang H, Parikh SA, Liu Y, et al
    Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL).
    Leuk Res. 2025;160:108133.
    PubMed     Abstract available
    
    
    
48. ITONAGA H, Miyazaki Y, Fujioka M, Kurosawa S, et al
    Differential impact of graft-versus-host disease on post-transplant outcomes of chronic myelomonocytic leukemia according to transplant procedures.
    Leuk Res. 2025;159:108134.
    PubMed     Abstract available
    
    
    October 2025
49. LI J, Li F, Zhang M, Wu Y, et al
    Exosomal miR-140-3p produced by bone marrow stromal cells affects acute myeloid leukemia cell growth and apoptosis by targeting SUZ12.
    Leuk Res. 2025;159:108122.
    PubMed     Abstract available
    
    
    
50. LEI Y, Tang Z, Reese JA, Jamy O, et al
    The role of interim bone marrow assessments in acute myeloid leukemia - A systematic review and meta-analysis.
    Leuk Res. 2025;159:108121.
    PubMed     Abstract available
    
    
    
51. LI J, Shi S, Zhu K, Zhe L, et al
    IGF2BP3 promotes acute myeloid leukemia cell progression by regulating Semaphorin 4D stability in an m6A-dependent manner.
    Leuk Res. 2025;159:108119.
    PubMed     Abstract available
    
    
    
52. UNAL D, Gumruk F, Aytac S, Kuskonmaz B, et al
    Infectious complications in pediatric acute lymphoblastic leukemia treatment: A comparison of ALL-IC BFM 2009 vs. modified St. Jude total XV in a single-center retrospective cohort study.
    Leuk Res. 2025;158:108120.
    PubMed     Abstract available
    
    
    
53. CLAIBORNE JP, Li D, Tsai HL, Ghiaur G, et al
    Efficacy and safety of blinatumomab for CD19?+?acute leukemias in patients historically excluded from clinical trials due to comorbidities.
    Leuk Res. 2025;157:108098.
    PubMed     Abstract available
    
    
    September 2025
54. MI R, Chen L, Wang L, Yang H, et al
    Multicenter retrospective analysis of the short-term efficacy and safety of the VAH regimen in the treatment of acute myeloid leukemia.
    Leuk Res. 2025;159:108114.
    PubMed     Abstract available
    
    
    
55. WANG L, Kurt M, Disher T, Liu FF, et al
    Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.
    Leuk Res. 2025;158:108113.
    PubMed     Abstract available
    
    
    
56. FUJIOKA M, Mishima H, Itonaga H, Hamaguchi Y, et al
    Genes with altered expression by 5-Aza treatment in myeloid leukemia cells through methylation in intron 1.
    Leuk Res. 2025;158:108112.
    PubMed     Abstract available
    
    
    
57. SHANG J, Chen WM, Liu S, Wang ZH, et al
    Corrigendum to "CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy" [Leuk. Res., 85 (2019) 106198].
    Leuk Res. 2025 Sep 23:108111. doi: 10.1016/j.leukres.2025.108111.
    PubMed    
    
    
    
58. ATALLAH EL, Sadek I, Wei D, Latremouille-Viau D, et al
    Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia.
    Leuk Res. 2025 Sep 5:108089. doi: 10.1016/j.leukres.2025.108089.
    PubMed     Abstract available
    
    
    
59. MOLINA A, Khanna V, Jensen A, Stehr H, et al
    Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomes.
    Leuk Res. 2025;156:107736.
    PubMed     Abstract available
    
    
    August 2025
60. YANG Q, Ding Z, Liu Y, Chen S, et al
    Effect of sorafenib on prognosis in patients with low-allelic-ratio FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2025;157:108088.
    PubMed     Abstract available
    
    
    
61. RAVIPATI S, Bakheet W, Woldie I, Gupta R, et al
    Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia.
    Leuk Res. 2025;157:108087.
    PubMed     Abstract available
    
    
    
62. ZHANG TY, Ge AY, Epstein MM, Patel SA, et al
    Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study.
    Leuk Res. 2025;157:108086.
    PubMed     Abstract available
    
    
    
63. KELLAWAY SG
    Targeting growth signals in leukemia: A case of mistaken identity.
    Leuk Res. 2025;157:107935.
    PubMed    
    
    
    
64. FATHI AT, Smith BD, Angiolillo A, Binder G, et al
    Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial.
    Leuk Res. 2025;157:107925.
    PubMed    
    
    
    
65. JABBAN Y, He R, Bessonen K, Greipp P, et al
    Clinical characteristics and prognostic significance of co-mutated SETBP1/GATA2 myeloid neoplasms.
    Leuk Res. 2025;155:107734.
    PubMed     Abstract available
    
    
    July 2025
66. YANG X, Huang R
    Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies.
    Leuk Res. 2025;157:107924.
    PubMed     Abstract available
    
    
    
67. LEI H, Xu H, Wang Y, Wu Y, et al
    CHK1-S, a splicing variant of CHK1, suppresses chronic myeloid leukemia.
    Leuk Res. 2025;156:107922.
    PubMed     Abstract available
    
    
    
68. MUDD TW, Diebold K, Parks K, Hardee M, et al
    Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with intermediate and adverse risk acute myeloid leukemia.
    Leuk Res. 2025;156:107920.
    PubMed    
    
    
    
69. TARIQ H, Vadasz B, Gao J, Chen YH, et al
    Clinicopathologic, genetic, and prognostic characteristics of single-hit versus multi-hit TP53-mutated chronic lymphocytic leukemia in the era of novel therapies.
    Leuk Res. 2025;156:107911.
    PubMed     Abstract available
    
    
    
70. STEINER L, Kaur N, Jann JC, Fabarius A, et al
    Inter-modality variance of blast quantification in patients with myelodysplastic neoplasms (MDS) and its impact on risk stratification and overall survival.
    Leuk Res. 2025;154:107718.
    PubMed     Abstract available
    
    
    June 2025
71. NAKAMURA F, Nakamura Y, Sasaki K, Yamazaki I, et al
    HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells.
    Leuk Res. 2025;156:107738.
    PubMed     Abstract available
    
    
    
72. REN Z, Vanhooren J, De Moerloose B, Lammens T, et al
    Involvement of THBS1 in myeloid sarcoma of acute myeloid leukemia.
    Leuk Res. 2025;155:107737.
    PubMed    
    
    
    
73. WANG H, Han C, Gong B, Liu Y, et al
    Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts.
    Leuk Res. 2025;155:107733.
    PubMed     Abstract available
    
    
    
74. AMIN MK, Khan MA, Khan FH, Zakir A, et al
    Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis.
    Leuk Res. 2025;155:107724.
    PubMed     Abstract available
    
    
    
75. CAVALLARO G, Salmoiraghi S, Cavagna R, Pavoni C, et al
    Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06.
    Leuk Res. 2025;153:107702.
    PubMed     Abstract available
    
    
    May 2025
76. HASLINGER S, Schinnerl D, Konig M, Inthal A, et al
    Identification of a novel amplified PAX5::RBPMS fusion gene in pediatric B-cell acute lymphoblastic leukemia.
    Leuk Res. 2025;154:107722.
    PubMed    
    
    
    
77. HAMMAMI MB, Qasim A, Shah A, Zhang H, et al
    Cutaneous manifestations of large granular lymphocytic leukemia: A case report and systematic review.
    Leuk Res. 2025;154:107720.
    PubMed    
    
    
    
78. KATO T, Imaizumi Y, Miyazaki Y
    Treatment strategy for indolent adult T-cell leukemia-lymphoma.
    Leuk Res. 2025;155:107714.
    PubMed     Abstract available
    
    
    
79. JOHNSON-ANSAH H, Charbonnier A, Etienne G, Roy L, et al
    Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.
    Leuk Res. 2025;154:107716.
    PubMed     Abstract available
    
    
    
80. SHICHIJO T, Yasunaga JI
    Stratagems of HTLV-1 for persistent infection and the resultant oncogenesis: Immune evasion and clonal expansion.
    Leuk Res. 2025;152:107680.
    PubMed     Abstract available
    
    
    April 2025
81. KONDO K, Najima Y, Sadato D, Hirama C, et al
    Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults.
    Leuk Res. 2025;153:107704.
    PubMed     Abstract available
    
    
    
82. AUBREY BJ, Blonquist T, McMasters M, Hobbs G, et al
    A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation.
    Leuk Res. 2025;153:107693.
    PubMed     Abstract available
    
    
    
83. ZHANG W, Cui Y, Wu J, Chen Y, et al
    Incidence and risk factors of venous thromboembolism in patients with acute Leukemia: A systematic review and meta-analysis.
    Leuk Res. 2025;153:107694.
    PubMed     Abstract available
    
    
    
84. VARGAS LCZ, Ortiz-Ortiz J, Martinez YA, Viguri GEC, et al
    Identification of ZNF384 as a regulator of epigenome in leukemia.
    Leuk Res. 2025;153:107691.
    PubMed     Abstract available
    
    
    
85. HIBINO Y, Fujisawa S, Fujimaki K, Hagihara M, et al
    Clinical applicability of the ELN2020 criteria for tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: insights from a multicenter retrospective study in real-world practice.
    Leuk Res. 2025;152:107689.
    PubMed     Abstract available
    
    
    
86. AL MALKI MM, Minden MD, Rich ES, Hill JE, et al
    Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study.
    Leuk Res. 2025;152:107690.
    PubMed     Abstract available
    
    
    March 2025
87. DHANGAR S, Shanmukhaiah C, Ghatanatti J, Sawant L, et al
    Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients.
    Leuk Res. 2025;152:107679.
    PubMed     Abstract available
    
    
    February 2025
88. KOGURE Y, Kataoka K
    Clinical and therapeutic significance of genetic profiling in adult T-cell leukemia/lymphoma.
    Leuk Res. 2025;151:107676.
    PubMed     Abstract available
    
    
    
89. THUY VT, Viet NL, Nghia NT, Cangelosi G, et al
    The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis.
    Leuk Res. 2025;151:107673.
    PubMed     Abstract available
    
    
    
90. WU Q, Zhong L, Zhang G, Han L, et al
    Complementing therapeutic strategies for acute myeloid leukemia: Signaling pathways and targets of traditional Chinese medicine.
    Leuk Res. 2025;151:107672.
    PubMed     Abstract available
    
    
    
91. SHI S, Zhou Q, Zhao D, Zarif M, et al
    Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion.
    Leuk Res. 2025;151:107665.
    PubMed     Abstract available
    
    
    
92. MAHMOOD NH, Kadir DH
    Sparsity regularization enhances gene selection and leukemia subtype classification via logistic regression.
    Leuk Res. 2025;150:107663.
    PubMed     Abstract available
    
    
    
93. KOMROKJI Z, Ali NA, Xie Z, Chan O, et al
    Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).
    Leuk Res. 2025;150:107662.
    PubMed     Abstract available
    
    
    January 2025
94. YOSHIDA N, Hida A, Sakata R
    Trends of changes in human T-cell leukemia virus type 1 epidemiology in Japan and globally.
    Leuk Res. 2025;150:107654.
    PubMed     Abstract available
    
    
    
95. YOSHIMITSU M
    Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia/lymphoma.
    Leuk Res. 2025;149:107653.
    PubMed     Abstract available
    
    
    
96. DENG A, Zhang F, Wang M, Jiang D, et al
    A novel KMT2A::DCP1A fusion gene in acute myeloid leukemia.
    Leuk Res. 2025;149:107645.
    PubMed    
    
    
    
97. EPSTEIN-PETERSON ZD, Gurumurthi A, Horwitz SM
    New treatments for adult T-cell leukemia/lymphoma.
    Leuk Res. 2025;149:107642.
    PubMed     Abstract available
    
    
    
98. FONTECHA MB, Del Rosario Anadon M, Lahitou IMM, Weich N, et al
    Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia.
    Leuk Res. 2025;149:107644.
    PubMed     Abstract available
    
    
    
99. WETERINGS DA, Rowan AG, Cook LB
    Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL).
    Leuk Res. 2025;148:107635.
    PubMed     Abstract available
    
    
    
100. WU H, Luo H, Wang M, Du Y, et al
     NAP1L5 promotes epithelial-mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia.
     Leuk Res. 2025;148:107623.
     PubMed     Abstract available
     
     
     December 2024
101. ZHAO R, Cui Y, Li D, Guo X, et al
     Anlotinib enhances the pro-apoptotic effect of APG-115 on acute myeloid leukemia cell lines by inhibiting the P13K/AKT signaling pathway.
     Leuk Res. 2024;149:107637.
     PubMed     Abstract available
     
     
     
102. SHAHZAD M, Iqbal Q, Amin MK, Irfan S, et al
     Outcomes of hematopoietic stem cell transplantation in primary plasma cell leukemia: A systematic review and meta-analysis.
     Leuk Res. 2024;148:107640.
     PubMed     Abstract available
     
     
     
103. LI M, Zhang S, Wei J, Liu M, et al
     The increase in the expression of circRNAs may contributes to a poor prognosis in acute myeloid leukemia: A systematic review and meta-analysis.
     Leuk Res. 2024;148:107639.
     PubMed     Abstract available
     
     
     
104. LI J, Fu S, Ye C, Li J, et al
     Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy.
     Leuk Res. 2024;148:107638.
     PubMed     Abstract available
     
     
     
105. KARUBE K, Sakihama S, Takatori M, Morichika K, et al
     Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era.
     Leuk Res. 2024;148:107634.
     PubMed     Abstract available
     
     
     
106. FUJI S
     Chemotherapy and allo-HSCT for young patients with aggressive ATL.
     Leuk Res. 2024;147:107596.
     PubMed     Abstract available
     
     
     November 2024
107. ROUZBAHANI M, Mousavi SA, Hajianfar G, Ghanaati A, et al
     Predictive modeling of outcomes in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation using machine learning techniques.
     Leuk Res. 2024;148:107619.
     PubMed     Abstract available
     
     
     
108. KIM JY, Vijayakumar KA, Cho GW
     Exploring the impact of methylation aging on acute myeloid leukemia: Insights from the aging clock.
     Leuk Res. 2024;148:107620.
     PubMed     Abstract available
     
     
     
109. QIAN S, Gong J, Shen X, Chen M, et al
     Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study.
     Leuk Res. 2024;148:107621.
     PubMed     Abstract available
     
     
     
110. WANG X, Chen T
     Diagnostic challenges and criteria application in a 70-year-old patient with oligo monocytic chronic granulomonocytic leukemia: A case report.
     Leuk Res. 2024;147:107616.
     PubMed    
     
     
     
111. MISHRA R, Calabrese C, Jain AG, Singh A, et al
     Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review.
     Leuk Res. 2024;146:107584.
     PubMed     Abstract available
     
     
     October 2024
112. ISFORT S, Gambacorti-Passerini C, Brummendorf TH, Smith BD, et al
     The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis.
     Leuk Res. 2024;147:107609.
     PubMed    
     
     
     
113. CHIEN KS, Rodriguez-Sevilla JJ, Alvarado Y, Montalban-Bravo G, et al
     A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.
     Leuk Res. 2024;147:107602.
     PubMed    
     
     
     
114. EL HAJJ H, Hermine O, Bazarbachi A
     Therapeutic advances for the management of adult T cell leukemia: Where do we stand?
     Leuk Res. 2024;147:107598.
     PubMed     Abstract available
     
     
     
115. LI T, Cui Q, Liu S, Li Z, et al
     Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.
     Leuk Res. 2024;145:107569.
     PubMed     Abstract available
     
     
     September 2024
116. PRIYA, Garg M, Talwar R, Bharadwaj M, et al
     Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis.
     Leuk Res. 2024;147:107595.
     PubMed     Abstract available
     
     
     
117. CHEN R, AlHumaid M, Daher-Reyes G, Atenafu EG, et al
     Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience.
     Leuk Res. 2024;147:107586.
     PubMed     Abstract available
     
     
     
118. XIAO Y, Xiao L, Xu X, Guan X, et al
     Development and validation of a predictive model for tumor lysis syndrome in childhood acute lymphoblastic leukemia.
     Leuk Res. 2024;146:107587.
     PubMed     Abstract available
     
     
     
119. FAIZ AS, Guo S, Sridharan A, Lin Y, et al
     Risk factors and mortality associated with venous thromboembolism in the elderly US population with chronic lymphocytic leukemia.
     Leuk Res. 2024;146:107585.
     PubMed     Abstract available
     
     
     
120. ACHAR RK, McCormick BJ, Dworkin E, Geramita EM, et al
     Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy.
     Leuk Res. 2024;146:107577.
     PubMed    
     
     
     
121. WU S, Liu F, Gai Y, Carter J, et al
     Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML.
     Leuk Res. 2024;144:107547.
     PubMed     Abstract available
     
     
     August 2024
122. DESAI A, Samara Y, Yang D, Ball B, et al
     Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation.
     Leuk Res. 2024;145:107565.
     PubMed     Abstract available
     
     
     
123. DIAZ MARTINEZ JP, de Maraumont TA, Camacho LM, Garcia L, et al
     Cost-effectiveness of blinatumomab for the treatment of B?precursor acute lymphoblastic leukemia pediatric patients with high?risk first?relapse in Mexico.
     Leuk Res. 2024;145:107560.
     PubMed     Abstract available
     
     
     
124. CINGELOVA S, Mikuskova E, Demitrovicova L, Mikudova V, et al
     Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide.
     Leuk Res. 2024;145:107567.
     PubMed     Abstract available
     
     
     
125. FU Q, Wang Y, Liu H, Gao H, et al
     Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3(mut) acute myeloid leukemia.
     Leuk Res. 2024;145:107564.
     PubMed     Abstract available
     
     
     
126. TRAVAGLINI S, Silvestrini G, Attardi E, Fanciulli M, et al
     Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.
     Leuk Res. 2024;145:107568.
     PubMed     Abstract available
     
     
     
127. SHIMIZU H, Kato J, Tanoue S, Kimura SI, et al
     Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
     Leuk Res. 2024;144:107562.
     PubMed     Abstract available
     
     
     
128. BOISCLAIR S, Zhou E, Naing P, Thakur R, et al
     Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML.
     Leuk Res. 2024;143:107545.
     PubMed     Abstract available
     
     
     
129. GALIENI P, Troiani E, Picardi P, Angelini M, et al
     Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT).
     Leuk Res. 2024;143:107541.
     PubMed     Abstract available
     
     
     
130. EDWARDS K, Manoussaka M, Sayed U, Tsertsvadze T, et al
     MD-1 downregulation is associated with reduced cell surface CD180 expression in CLL.
     Leuk Res. 2024;143:107540.
     PubMed     Abstract available
     
     
     
131. VIANNA DT, Reis Monte-Mor BDC, Noronha EP, Gutiyama LM, et al
     Molecular characterization of V(D)J rearrangements in immature acute leukemias.
     Leuk Res. 2024;143:107521.
     PubMed     Abstract available
     
     
     July 2024
132. CUI H, Ma Y, Han S, Zhang X, et al
     Arsenic trioxide regulates the glycolytic pathway to treat acute promyelocytic leukemia by inhibiting RPL22L1.
     Leuk Res. 2024;144:107550.
     PubMed     Abstract available
     
     
     
133. MOLICA M, Perrone S, Rossi M, Giannarelli D, et al
     The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis.
     Leuk Res. 2024;144:107549.
     PubMed     Abstract available
     
     
     
134. KONG C, Wu M, Lu Q, Ke B, et al
     PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
     Leuk Res. 2024;144:107548.
     PubMed     Abstract available
     
     
     
135. MESTRUM SGC, Roanalis BYV, de Wit NCJ, Drent RJM, et al
     MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio.
     Leuk Res. 2024;142:107520.
     PubMed     Abstract available
     
     
     June 2024
136. PARMAR K, Kundu R, Maiti A, Ball S, et al
     Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia.
     Leuk Res. 2024;144:107546.
     PubMed     Abstract available
     
     
     
137. XU Z, Zhang T, Hao J, Liu D, et al
     Identification of clonal relationship and prognostic significance in acute myeloid leukemia patients with concomitant increase in mast cells.
     Leuk Res. 2024;143:107539.
     PubMed    
     
     
     
138. SHIN DY, Park S, Jang E, Kong JH, et al
     Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.
     Leuk Res. 2024;143:107542.
     PubMed     Abstract available
     
     
     
139. JESTRABEK H, Kohlhas V, Hallek M, Nguyen PH, et al
     Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia.
     Leuk Res. 2024;143:107531.
     PubMed     Abstract available
     
     
     
140. PANDA T, Rainchwar S, Singh R, Singh A, et al
     Real world outcome of B ALL with t (1; 19) (q23; p13)/TCF3::PBX1 in adolescents and adults treated with intensive regimes.
     Leuk Res. 2024;141:107506.
     PubMed     Abstract available
     
     
     May 2024
141. ODUTOLA PO, Olorunyomi PO, Olorunyomi I
     Single vs double umbilical cord blood transplantation in acute leukemia: Systematic review and meta-analysis.
     Leuk Res. 2024;142:107517.
     PubMed     Abstract available
     
     
     
142. RISUENO A, See WL, Bluemmert I, de Botton S, et al
     Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
     Leuk Res. 2024;140:107497.
     PubMed     Abstract available
     
     
     April 2024
143. SUN M, Li S, Liu Z, Ma S, et al
     Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation.
     Leuk Res. 2024;142:107507.
     PubMed     Abstract available
     
     
     
144. INDRAN T, Das T, Muirhead J, O'Brien M, et al
     Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34(+) and CD3(+) donor chim
     Leuk Res. 2024;142:107504.
     PubMed     Abstract available
     
     
     
145. MOHEBBI A, Shahriyary F, Farrokhi V, Bandar B, et al
     A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
     Leuk Res. 2024;141:107505.
     PubMed     Abstract available
     
     
     
146. ZAD Z, Bonecker S, Wang T, Zalcberg I, et al
     Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models.
     Leuk Res. 2024;141:107502.
     PubMed    
     
     
     
147. BERTON G, Sedaki B, Collomb E, Benachour S, et al
     Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
     Leuk Res. 2024;141:107500.
     PubMed     Abstract available
     
     
     
148. DONG S, Premnath N, Sadeghi N, Kainthla R, et al
     Racial and ethnic disparities in Acute Myeloid Leukemia: 15-year experience at a safety net hospital system.
     Leuk Res. 2024;141:107503.
     PubMed     Abstract available
     
     
     
149. ASHOURI K, Ginosyan AA, Chu M, Hom B, et al
     Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study.
     Leuk Res. 2024;141:107501.
     PubMed     Abstract available
     
     
     
150. HU X, Cao P, Wang F, Wang T, et al
     Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation.
     Leuk Res. 2024;141:107499.
     PubMed     Abstract available
     
     
     
151. SMITH BD, Brummendorf TH, Roboz GJ, Gambacorti-Passerini C, et al
     Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
     Leuk Res. 2024;139:107481.
     PubMed     Abstract available
     
     
     
152. MORSY MM, Azzam AY, Elamin O, Elswedy A, et al
     Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
     Leuk Res. 2024;140:107498.
     PubMed     Abstract available
     
     
     March 2024
153. YIGIT KAYA S, Mutlu YG, Malkan UY, Mehtap O, et al
     Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
     Leuk Res. 2024;140:107495.
     PubMed     Abstract available
     
     
     
154. MUTHIAH C, Narra R, Atallah E, Juan W, et al
     Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
     Leuk Res. 2024;140:107496.
     PubMed     Abstract available
     
     
     
155. BRUNETTI M, Iasenza IA, Jenner AL, Raynal NJ, et al
     Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.
     Leuk Res. 2024;140:107485.
     PubMed     Abstract available
     
     
     
156. IKOMA-COLTURATO MRV, Severino AR, Dos Santos Tosi JF, Bertolucci CM, et al
     Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemia.
     Leuk Res. 2024;140:107482.
     PubMed    
     
     
     
157. GARCIA-MANERO G, Kazmierczak M, Wierzbowska A, Fong CY, et al
     Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
     Leuk Res. 2024 Mar 12:107480. doi: 10.1016/j.leukres.2024.107480.
     PubMed     Abstract available
     
     
     
158. WAN CL, Huang YH, Huang SM, Xu YL, et al
     Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
     Leuk Res. 2024;139:107483.
     PubMed     Abstract available
     
     
     
159. PAN L, Li Y, Gao H, Lai X, et al
     Clinical features and management of germline CEBPA-mutated carriers.
     Leuk Res. 2024;138:107453.
     PubMed     Abstract available
     
     
     
160. SIDI Y, Dong C, Wu Y, Faller DV, et al
     A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
     Leuk Res. 2024;138:107465.
     PubMed     Abstract available
     
     
     February 2024
161. BOURNE G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, et al
     Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
     Leuk Res. 2024;139:107467.
     PubMed     Abstract available
     
     
     
162. ZHONG S, Kurish H, Walchack R, Li H, et al
     Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
     Leuk Res. 2024;139:107468.
     PubMed     Abstract available
     
     
     
163. OSMAN AEG, Rets A, Patel AB
     KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia.
     Leuk Res. 2024;138:107466.
     PubMed    
     
     
     
164. SANCHEZ-PETITTO G, Goloubeva OG, Masur J, Childress J, et al
     Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
     Leuk Res. 2024;138:107456.
     PubMed     Abstract available
     
     
     
165. SUDO H, Tonoyama Y, Ikebe E, Hasegawa H, et al
     Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteins.
     Leuk Res. 2024;138:107454.
     PubMed     Abstract available
     
     
     
166. GOULART H, Sastow D, Moshier E, Martin L, et al
     Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement.
     Leuk Res. 2024;137:107452.
     PubMed     Abstract available
     
     
     
167. ELGHETANY MT, Patnaik MM, Khoury JD
     Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
     Leuk Res. 2024;137:107441.
     PubMed     Abstract available
     
     
     
168. RAMOS-CILLAN S, Lainez-Gonzalez D, Solan L, Blas C, et al
     When the devil is in the details: Similarities and differences between WHO and ICC classifications of AML.
     Leuk Res. 2024;137:107440.
     PubMed    
     
     
     January 2024
169. BOUCHER L, Rozalska L, Sorel N, Olivier G, et al
     Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
     Leuk Res. 2024;137:107439.
     PubMed    
     
     
     
170. OH I, Hatano K, Ikeda T, Toda Y, et al
     Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
     Leuk Res. 2024;137:107438.
     PubMed    
     
     
     
171. DIDI I, Alliot JM, Dumas PY, Vergez F, et al
     Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
     Leuk Res. 2024;136:107437.
     PubMed     Abstract available
     
     
     
172. KLINK AJ, Gajra A, Knoth RL, Marshall L, et al
     Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
     Leuk Res. 2024 Jan 9:107430. doi: 10.1016/j.leukres.2023.107430.
     PubMed    
     
     
     
173. KUSNE Y, Lasho T, Finke C, Patnaik MM, et al
     VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
     Leuk Res. 2024;136:107432.
     PubMed    
     
     
     
174. KHANNA V, Lu R, Kumar J, Molina A, et al
     The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
     Leuk Res. 2024;136:107433.
     PubMed     Abstract available
     
     
     December 2023
175. NOTARANTONIO AB, Roth-Guepin G, Bonmati C, Divoux M, et al
     A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
     Leuk Res. 2023;135:107405.
     PubMed    
     
     
     November 2023
176. ASHBY M, Fleming S, Teh TC, Tiong IS, et al
     Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.
     Leuk Res. 2023;136:107429.
     PubMed    
     
     
     
177. URBINO I, Secreto C, Apolito V, Olivi M, et al
     Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
     Leuk Res. 2023 Nov 18:107421. doi: 10.1016/j.leukres.2023.107421.
     PubMed    
     
     
     
178. ZHAO D, Zhou Q, Zarif M, Eladl E, et al
     AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
     Leuk Res. 2023;134:107376.
     PubMed     Abstract available
     
     
     October 2023
179. RAVINDRA A, Acharya L, Loeffler B, Mott S, et al
     Venetoclax-based therapy in treatment-naive and relapsed/refractory acute myeloid leukemia.
     Leuk Res. 2023;135:107407.
     PubMed     Abstract available
     
     
     
180. ANSARI F, Behfar M, Jafari L, Mohseni R, et al
     A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.
     Leuk Res. 2023;135:107416.
     PubMed     Abstract available
     
     
     
181. ZHANG F, Du H, Hu C, Song Y, et al
     A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes.
     Leuk Res. 2023;135:107404.
     PubMed     Abstract available
     
     
     
182. SHERBAN A, Fredman D, Shimony S, Yeshurun M, et al
     Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
     Leuk Res. 2023;133:107368.
     PubMed     Abstract available
     
     
     
183. DE LA GARZA-SALAZAR F, Colunga-Pedraza PR, Gomez-Almaguer D, Garcia-Zarate VA, et al
     Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study.
     Leuk Res. 2023;133:107373.
     PubMed     Abstract available
     
     
     
184. BHATTACHARJEE U, Jandial A, Singh C, Lekshmon KS, et al
     Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
     Leuk Res. 2023;133:107367.
     PubMed     Abstract available
     
     
     September 2023
185. JIMENEZ-VICENTE C, Martinez-Roca A, Pomares H, Castano-Diez S, et al
     Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
     Leuk Res. 2023;135:107403.
     PubMed    
     
     
     
186. JAMY OH, Kasner M, Wall S, Ingram S, et al
     Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions.
     Leuk Res. 2023;134:107393.
     PubMed     Abstract available
     
     
     
187. GURNEY M, Greipp PT, Gliem T, Knudson R, et al
     TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
     Leuk Res. 2023;134:107391.
     PubMed    
     
     
     
188. SINGH C, Karunakaran P, Yanamandra U, Jindal N, et al
     Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
     Leuk Res. 2023;134:107392.
     PubMed     Abstract available
     
     
     
189. PATEL SA, Bello E, Wilks A, Gerber JM, et al
     Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.
     Leuk Res. 2023;134:107388.
     PubMed     Abstract available
     
     
     
190. HIRT CK, Padmanabha N, Michaels PD
     Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia.
     Leuk Res. 2023;132:107357.
     PubMed    
     
     
     
191. BRANDWEIN JM, Ebeling K, Ding L, Liew E, et al
     Changing frontline AML treatment patterns from 2013 to 2022.
     Leuk Res. 2023;132:107354.
     PubMed     Abstract available
     
     
     
192. XIE W, Wang Z, Guo X, Guan H, et al
     MiR-409-3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10.
     Leuk Res. 2023;132:107350.
     PubMed     Abstract available
     
     
     August 2023
193. KHADADAH FM, Cerquozzi S, Olney HJ, Fraga C, et al
     Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
     Leuk Res. 2023;133:107374.
     PubMed     Abstract available
     
     
     
194. BOULIGNY IM, Murray G, Ho T, Doyel M, et al
     Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
     Leuk Res. 2023;134:107370.
     PubMed    
     
     
     
195. ZHAO ZY, Tang N, Lin LE
     A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review.
     Leuk Res. 2023;133:107369.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum